Details for New Drug Application (NDA): 217110
✉ Email this page to a colleague
NDA 217110 describes IVRA, which is a drug marketed by Apotex and is included in one NDA. There is one patent protecting this drug. Additional details are available on the IVRA profile page.
The generic ingredient in IVRA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.
The generic ingredient in IVRA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.
Summary for 217110
| Tradename: | IVRA |
| Applicant: | Apotex |
| Ingredient: | melphalan hydrochloride |
| Patents: | 1 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 90MG BASE/ML (EQ 90MG BASE/ML) | ||||
| Approval Date: | Aug 18, 2023 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Jun 29, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
